Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial.
Chiuppesi F, Zaia JA, Frankel PH, Stan R, Drake J, Williams B, Acosta AM, Francis K, Taplitz RA, Dickter JK, Dadwal S, Puing AG, Nanayakkara DD, Ash P, Cui Y, Contreras H, La Rosa C, Tiemann K, Park Y, Medina J, Iniguez A, Zhou Q, Karpinski V, Johnson D, Faircloth K, Kaltcheva T, Nguyen J, Kha M, Nguyen VH, Francisco SO, Grifoni A, Wong A, Sette A, Wussow F, Diamond DJ. Chiuppesi F, et al. Among authors: frankel ph. Lancet Microbe. 2022 Apr;3(4):e252-e264. doi: 10.1016/S2666-5247(22)00027-1. Epub 2022 Mar 9. Lancet Microbe. 2022. PMID: 35287430 Free PMC article. Clinical Trial.
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Hardwick NR, Frankel P, Ruel C, Kilpatrick J, Tsai W, Kos F, Kaltcheva T, Leong L, Morgan R, Chung V, Tinsley R, Eng M, Wilczynski S, Ellenhorn JDI, Diamond DJ, Cristea M. Hardwick NR, et al. Clin Cancer Res. 2018 Mar 15;24(6):1315-1325. doi: 10.1158/1078-0432.CCR-17-2709. Epub 2018 Jan 4. Clin Cancer Res. 2018. PMID: 29301826 Free PMC article. Clinical Trial.
Severe Acute Respiratory Syndrome Coronavirus 2-Specific Monoclonal Antibody for the Treatment of Mild to Moderate Coronavirus Disease 2019 in Cancer Patients: A Single-Center Experience.
Puing AG, Ho S, Frankel P, Tegtmeier B, Martin A, Ross J, Nanayakkara D, Dickter J, Seto T, Nakamura R, Taplitz R, Dadwal S. Puing AG, et al. J Infect Dis. 2022 Jan 18;225(2):352-354. doi: 10.1093/infdis/jiab406. J Infect Dis. 2022. PMID: 34379763 Free PMC article. No abstract available.
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates.
Chiuppesi F, Nguyen VH, Park Y, Contreras H, Karpinski V, Faircloth K, Nguyen J, Kha M, Johnson D, Martinez J, Iniguez A, Zhou Q, Kaltcheva T, Frankel P, Kar S, Sharma A, Andersen H, Lewis MG, Shostak Y, Wussow F, Diamond DJ. Chiuppesi F, et al. NPJ Vaccines. 2022 Jan 21;7(1):7. doi: 10.1038/s41541-022-00436-6. NPJ Vaccines. 2022. PMID: 35064109 Free PMC article.
Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants.
Chiuppesi F, Zaia JA, Faircloth K, Johnson D, Ly M, Karpinski V, La Rosa C, Drake J, Marcia J, Acosta AM, Dempsey S, Taplitz RA, Zhou Q, Park Y, Ortega Francisco S, Kaltcheva T, Frankel PH, Rosen S, Wussow F, Dadwal S, Diamond DJ. Chiuppesi F, et al. Among authors: frankel ph. iScience. 2022 Aug 19;25(8):104745. doi: 10.1016/j.isci.2022.104745. Epub 2022 Jul 11. iScience. 2022. PMID: 35846380 Free PMC article.
Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM, Somlo G, Yost SE, Frankel PH, Ruel C, Cui Y, Murga M, Tang A, Martinez N, Kruper L, Tumyan L, Schmolze D, Yeon C, Yuan Y, Waisman JR, Mortimer J. Lavasani SM, et al. Among authors: frankel ph. Cancer. 2023 Mar 1;129(5):740-749. doi: 10.1002/cncr.34589. Epub 2022 Dec 14. Cancer. 2023. PMID: 36517940 Free PMC article. Clinical Trial.
Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer.
Egelston CA, Guo W, Yost SE, Ge X, Lee JS, Frankel PH, Cui Y, Ruel C, Schmolze D, Murga M, Tang A, Martinez N, Karimi M, Somlo G, Lee PP, Waisman JR, Yuan Y. Egelston CA, et al. Among authors: frankel ph. Cancer Immunol Immunother. 2023 Sep;72(9):3013-3027. doi: 10.1007/s00262-023-03470-y. Epub 2023 Jun 9. Cancer Immunol Immunother. 2023. PMID: 37294342 Free PMC article. Clinical Trial.
176 results